Developer of therapeutics designed to stop the progression of cancer and activate the healthy immune system. The company's services uses active ingredients are based on Angiocidin, a protein which has been shown to activate monocytes and drive terminal differentiation of leukemia cells, enabling AML patients to get proper treatement against cancer.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Accelerator/Incubator | 21-Feb-2018 | Completed | Startup | |||
2. Grant | 01-Jan-2013 | 00000 | Completed | Startup | ||
1. Grant | 01-Jan-2011 | $100K | Completed | Startup |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Deni Zodda | Chief Executive Officer | ||
George Tuszynski Ph.D | Founder |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
MassChallenge | Accelerator/Incubator | 000 0000 | 000000 0 | ||
U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 | ||
Science Center | Accelerator/Incubator | 000 0000 | 000000 0 |